OneThree Biotech
AI-driven biotech firm, OneThree, revolutionizes drug discovery by predicting therapeutics and enhancing clinical success.
Founded
2018AI-driven biotech firm, OneThree, revolutionizes drug discovery by predicting therapeutics and enhancing clinical success.
Founded in 2018 and headquartered in New York, OneThree Biotech leverages biology-driven artificial intelligence to revolutionize drug discovery. The company's core mission is to uncover new therapeutic insights by integrating over 30 types of chemical, biological, and clinical data. OneThree Biotech's platform predicts potential therapeutics and identifies mechanisms driving efficacy, significantly enhancing accuracy, interpretability, and the likelihood of clinical success.
Notable figures affiliated with OneThree Biotech include its founders and a team of experts in AI and biotechnology. The company has garnered attention from leading industry partners and investors. Key achievements include over 20 peer-reviewed publications, successful case studies, and validated predictions in cells, animals, and clinical settings. OneThree Biotech's impact is evident in its ability to advance in-house programs and contribute novel biological discoveries to the pharmaceutical industry.
Companies similar to OneThree Biotech include Proxima, Aureka Biotechnologies, Owkin and BioAI Health.
OneThree Biotech was founded in 2018.
OneThree Biotech's headquarters is located in New York City, NY, US.
OneThree Biotech's most recent funding round was for $2.5M (USD) in March 2020.
As of Mar 26, 2020, OneThree Biotech has disclosed funding of $2.5M (USD). Undisclosed round amounts are excluded.
OneThree Biotech has 31 employees as of Feb 5, 2024.
BioAI Health
bioaihealth.com
